MA48944A - Forme cristalline de n-butyldéoxygalactonojirimycine - Google Patents

Forme cristalline de n-butyldéoxygalactonojirimycine

Info

Publication number
MA48944A
MA48944A MA048944A MA48944A MA48944A MA 48944 A MA48944 A MA 48944A MA 048944 A MA048944 A MA 048944A MA 48944 A MA48944 A MA 48944A MA 48944 A MA48944 A MA 48944A
Authority
MA
Morocco
Prior art keywords
butyldeoxygalactonojirimycin
crystalline form
crystalline
butyldeoxygalactonojirimycin crystalline
Prior art date
Application number
MA048944A
Other languages
English (en)
Other versions
MA48944B1 (fr
Inventor
Vitor Oliveira
Ivan Pogorelic
Jean-Paul Roduit
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA48944A publication Critical patent/MA48944A/fr
Publication of MA48944B1 publication Critical patent/MA48944B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MA48944A 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine MA48944B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017063287 2017-06-01
PCT/EP2018/064365 WO2018220131A1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine
EP18728624.0A EP3630725B1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine

Publications (2)

Publication Number Publication Date
MA48944A true MA48944A (fr) 2020-04-08
MA48944B1 MA48944B1 (fr) 2025-12-31

Family

ID=62492649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48944A MA48944B1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine

Country Status (27)

Country Link
US (2) US11306058B2 (fr)
EP (1) EP3630725B1 (fr)
JP (2) JP6937850B2 (fr)
KR (1) KR102612650B1 (fr)
CN (1) CN110799497A (fr)
AU (1) AU2018278247B2 (fr)
CA (1) CA3065147A1 (fr)
CL (1) CL2019003478A1 (fr)
DK (1) DK3630725T3 (fr)
EA (1) EA201992807A1 (fr)
ES (1) ES3059191T3 (fr)
FI (1) FI3630725T3 (fr)
HR (1) HRP20251697T1 (fr)
IL (1) IL270961B2 (fr)
LT (1) LT3630725T (fr)
MA (1) MA48944B1 (fr)
MX (1) MX2019014427A (fr)
MY (1) MY201196A (fr)
NZ (1) NZ760100A (fr)
PH (1) PH12019502635A1 (fr)
PL (1) PL3630725T3 (fr)
PT (1) PT3630725T (fr)
RS (1) RS67675B1 (fr)
SI (1) SI3630725T1 (fr)
TW (1) TWI770184B (fr)
UA (1) UA125938C2 (fr)
WO (1) WO2018220131A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3630725T3 (pl) * 2017-06-01 2026-03-23 Idorsia Pharmaceuticals Ltd Postać krystaliczna n-butylodeoksygalaktonojirymycyny
WO2021061701A1 (fr) 2019-09-25 2021-04-01 Teva Pharmaceuticals International Gmbh Formes à l'état solide de sels de lucérastat et leur procédé de préparation
WO2025017212A1 (fr) 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Inhibiteurs de synthase de glucosyltransférase de céramide d'udp-glucose (ugcg) dans le traitement du cancer
TR2024011149A1 (tr) * 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086413A1 (fr) * 1990-06-29 1991-12-30 Yohji Ezure Derives piperidine
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
EP3782655A1 (fr) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
DE602007008870D1 (de) 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
ITMI20122090A1 (it) 2012-12-06 2014-06-07 Dipharma Francis Srl Sintesi di un inibitore delle glicosiltransferasi
PL3630725T3 (pl) * 2017-06-01 2026-03-23 Idorsia Pharmaceuticals Ltd Postać krystaliczna n-butylodeoksygalaktonojirymycyny

Also Published As

Publication number Publication date
WO2018220131A1 (fr) 2018-12-06
LT3630725T (lt) 2026-01-12
CN110799497A (zh) 2020-02-14
NZ760100A (en) 2026-03-27
EP3630725A1 (fr) 2020-04-08
JP6937850B2 (ja) 2021-09-22
IL270961B2 (en) 2025-03-01
JP2021185184A (ja) 2021-12-09
UA125938C2 (uk) 2022-07-13
FI3630725T3 (fi) 2026-01-27
KR20200011992A (ko) 2020-02-04
US11713297B2 (en) 2023-08-01
PT3630725T (pt) 2026-01-27
CL2019003478A1 (es) 2020-06-05
MA48944B1 (fr) 2025-12-31
AU2018278247B2 (en) 2022-07-28
IL270961A (en) 2020-01-30
ES3059191T3 (en) 2026-03-19
EP3630725B1 (fr) 2025-10-29
DK3630725T3 (da) 2026-02-09
CA3065147A1 (fr) 2018-12-06
KR102612650B1 (ko) 2023-12-11
BR112019025125A2 (pt) 2020-07-21
MX2019014427A (es) 2020-02-05
IL270961B1 (en) 2024-11-01
US20220002245A1 (en) 2022-01-06
TWI770184B (zh) 2022-07-11
US20200140385A1 (en) 2020-05-07
US11306058B2 (en) 2022-04-19
HRP20251697T1 (hr) 2026-02-27
RS67675B1 (sr) 2026-02-27
JP2020521796A (ja) 2020-07-27
SI3630725T1 (sl) 2026-01-30
EA201992807A1 (ru) 2020-05-20
PH12019502635A1 (en) 2020-07-13
AU2018278247A1 (en) 2020-01-16
PL3630725T3 (pl) 2026-03-23
TW201902876A (zh) 2019-01-16
JP7373529B2 (ja) 2023-11-02
MY201196A (en) 2024-02-09

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
EP3722358A4 (fr) Composition
EP3672912A4 (fr) Molybdotungstate de métal de transition cristallin
DK3473674T3 (da) Polypropylensammensætning
PT3687999T (pt) Derivados de rapamicina
DK3697376T3 (da) Sammensætning
EP3337383A4 (fr) Estimation de forme de paupière
PL3978483T3 (pl) Krystaliczny solwat toluenowy (S)-afoksolaneru
EP3548487A4 (fr) Forme polymorphe de sépiaptérine
EP3514627A4 (fr) Composition photo-polymère
EP3455077C0 (fr) Impression
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3588499A4 (fr) Composition photopolymère
EP3692557A4 (fr) Ultracondensateur en forme de puce
EP3430073A4 (fr) Composition de polyaryléthercétone
EP3668876A4 (fr) Forme polymorphe de tg02
EP3390422A4 (fr) Formes cristallines de lnt
MA46567A (fr) Formes cristallines de l'éravacycline
EP3573117A4 (fr) Composition d'encre
EP3898809C0 (fr) Composition de polypropylène
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
EP3543260A4 (fr) Composition photopolymère
MA46266A (fr) Formes cristallines
EP3675653C0 (fr) Composition antimycotoxine
EP3789389A4 (fr) Forme cristalline de dérivé de thiophène